| abstract |
The present invention relates to novel interleukin 2 (IL-2) mutants and uses thereof. In particular, the present invention relates to IL-2 mutants having reduced IL-2R [alpha] receptor binding ability and/or increased IL-2R [beta] receptor binding ability compared to wild type IL-2. The present invention also provides a fusion protein, an immune-conjugate comprising the IL-2 mutant, and a nucleic acid encoding the IL-2 mutant, a vector and a host cell comprising the nucleic acid. The invention further provides a method of making the IL-2 mutant, a pharmaceutical composition comprising the IL-2 mutant, and a therapeutic use of the mutant. |